Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $763,749 | $829,509 | $817,698 | $648,677 |
| % Growth | -7.9% | 1.4% | 26.1% | – |
| Cost of Goods Sold | $296,039 | $346,165 | $305,269 | $268,842 |
| Gross Profit | $467,710 | $483,344 | $512,429 | $379,835 |
| % Margin | 61.2% | 58.3% | 62.7% | 58.6% |
| R&D Expenses | $26,194 | $25,365 | $24,311 | $27,900 |
| G&A Expenses | $136,519 | $125,269 | $109,992 | $90,642 |
| SG&A Expenses | $158,256 | $147,023 | $129,985 | $103,355 |
| Sales & Mktg Exp. | $21,737 | $21,754 | $19,993 | $12,713 |
| Other Operating Expenses | $103,715 | $90,702 | $102,285 | $67,188 |
| Operating Expenses | $288,165 | $263,090 | $256,581 | $198,443 |
| Operating Income | $179,545 | $220,254 | $255,848 | $181,392 |
| % Margin | 23.5% | 26.6% | 31.3% | 28% |
| Other Income/Exp. Net | -$1,855 | $154 | $2,119 | $1,236 |
| Pre-Tax Income | $177,690 | $220,408 | $257,967 | $182,628 |
| Tax Expense | $40,814 | $50,109 | $58,302 | $29,551 |
| Net Income | $136,881 | $170,335 | $199,669 | $153,077 |
| % Margin | 17.9% | 20.5% | 24.4% | 23.6% |
| EPS | 2.67 | 3.2 | 3.73 | 2.76 |
| % Growth | -16.6% | -14.2% | 35.1% | – |
| EPS Diluted | 2.67 | 3.2 | 3.73 | 2.76 |
| Weighted Avg Shares Out | 51,266 | 53,192 | 53,466 | 55,404 |
| Weighted Avg Shares Out Dil | 51,266 | 53,192 | 53,466 | 55,404 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27 | $7 | $6 | $68 |
| Interest Expense | $2,433 | $948 | $844 | $907 |
| Depreciation & Amortization | $20,910 | $18,544 | $17,592 | $16,409 |
| EBITDA | $199,615 | $238,017 | $271,330 | $196,562 |
| % Margin | 26.1% | 28.7% | 33.2% | 30.3% |